These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21067806)

  • 1. Is intensive LDL-cholesterol lowering beneficial and safe?
    Cheung BM; Lam KS
    Lancet; 2010 Nov; 376(9753):1622-4. PubMed ID: 21067806
    [No Abstract]   [Full Text] [Related]  

  • 2. [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk].
    Olsson AG
    Lakartidningen; 2011 Jun 1-14; 108(22-23):1240-3. PubMed ID: 21786498
    [No Abstract]   [Full Text] [Related]  

  • 3. [Statins plus cholesterol resorption inhibitor. LDL goal values attainable].
    MMW Fortschr Med; 2002 Sep; 144(38):56. PubMed ID: 12395708
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipid-lowering study raises issues of therapy's value.
    Thompson CA
    Am J Health Syst Pharm; 2008 Apr; 65(7):594-5. PubMed ID: 18359962
    [No Abstract]   [Full Text] [Related]  

  • 5. [Statin and absorption inhibitor work synergistically. More risk patient reach LDL cholesterol goal value].
    MMW Fortschr Med; 2007 Apr; 149(17):56-7. PubMed ID: 17674912
    [No Abstract]   [Full Text] [Related]  

  • 6. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
    Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Say no to the extremes in the debate on lipid reduction].
    Hjemdahl P; Allhammar A; Eklund J; Forslund T; Hulting J; Kahan T; Martinsson A; Malmström R; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
    Lakartidningen; 2011 Sep 7-13; 108(36):1664-5. PubMed ID: 22032007
    [No Abstract]   [Full Text] [Related]  

  • 8. Begin with the real-world patients of non-goal-achieved hypercholesterolemia in taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study.
    Huang JC; Lee TY; Liou MJ; Lin CM; Pei D; Chen ZC; Liu RT; Kwok CF
    Curr Med Res Opin; 2011 Aug; 27(8):1645-51. PubMed ID: 21699369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Strengthened support for statin therapy as secondary prevention. Doubtful evidence for more intensive lowering of cholesterol levels].
    Håkansson J
    Lakartidningen; 2011 Jun 1-14; 108(22-23):1234-5. PubMed ID: 21786497
    [No Abstract]   [Full Text] [Related]  

  • 10. [On the current debate on lowering LDL cholesterol with ezetimibe].
    Breuer HW
    Dtsch Med Wochenschr; 2010 Nov; 135(44):2201; author reply 2202. PubMed ID: 20979008
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins].
    Sudhop T; von Bergmann K
    MMW Fortschr Med; 2003 Apr; 145(16):48-50. PubMed ID: 14606402
    [No Abstract]   [Full Text] [Related]  

  • 13. Improve-it: Full disclosures?
    Nicot P; Guerbaai RA; Ennezat PV
    Int J Cardiol; 2015 Dec; 201():380-1. PubMed ID: 26310982
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.
    Averna M; Missault L; Vaverkova H; Farnier M; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Taggart W; Brudi P
    Diab Vasc Dis Res; 2011 Oct; 8(4):262-70. PubMed ID: 21859750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sequelae of the CARDS Study. LDL of 110 mg/dl still too high?].
    Klose G
    MMW Fortschr Med; 2004 Jun; 146(26):14. PubMed ID: 15529683
    [No Abstract]   [Full Text] [Related]  

  • 16. LDL-Cholesterol is the King.
    Goumas GS
    Angiology; 2009; 60(3):387-8. PubMed ID: 19497926
    [No Abstract]   [Full Text] [Related]  

  • 17. Simvastatin + ezetimibe: a combination with no proven advantages.
    Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17460829
    [No Abstract]   [Full Text] [Related]  

  • 18. [Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
    MMW Fortschr Med; 2005 Aug; 147(33-34):50-1. PubMed ID: 16138640
    [No Abstract]   [Full Text] [Related]  

  • 19. LDL cholesterol goals in high-risk patients: how low do we go and how do we get there?
    Besseling J; van Capelleveen J; Kastelein JJ; Hovingh GK
    Drugs; 2013 Mar; 73(4):293-301. PubMed ID: 23494186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lowering LDL cholesterol is good, but how and in whom?
    Stone NJ; Lloyd-Jones DM
    N Engl J Med; 2015 Apr; 372(16):1564-5. PubMed ID: 25773740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.